|
Bangalore, India
March 21st, 2007
 Avestha
Gengraine Technologies Pvt. Ltd. (Avesthagen), a leading
biotechnology company today began construction of its new
250,000 square feet corporate headquarters and state-of-the-art
R&D center at the International Technology Park, Whitefield,
Bangalore. Avesthagen-One, as the building will be known,
promises to be iconic in more than one aspects Avesthagen-One
has been designed by the world-renowned Architect Hafeez
Contractor and clearly represents what the company stands for
viz. uniqueness, open-mindedness, trust, partnership and
innovation.
On March 21st, 2001 Avesthagen’s business operations at the
International technology park were inaugurated by Shri. S.M.
Krishna, the CM of Karnataka state.
Currently, Avesthagen operates out of 50,000 square feet at the
International technology park. Keeping in view its global
ambitions, aggressive growth strategy and plans, the management
felt that it was imperative to construct a R&D centre dedicated
to Innovation with its Systems Biology Platforms. Avesthagen at
present employs 250 people worldwide and plans to add up another
400 employees within the next 6 to 9 months.
The fourteen floors high Avesthagen-One is designed to make use
of natural elements such as trees, fountains, natural lighting,
natural ventilation that will offer a tranquil setting, which
will allow researchers to explore and interact without bias or
fear. The settings are intended to allow the company’s creative
workforce to generate ideas and innovate as also to educate and
promote brand awareness. They will also help build community and
trust. All these settings are vital to increase productivity in
a contemporary work environment.
Keeping with the tradition of Bangalore, Avesthagen-One will be
one of the leafiest buildings in the city that will have
strategically designed gathering spaces, positioned to serve
areas for concentration, work, laboratories, touchdown and
interaction.
Since its inception Avesthagen
has grown into one of India's leading healthcare technology
group in India, pursuing its vision of convergence of food,
pharma and population genetics leading to preventive
personalized medicine. Its activities include, in addition to
its agri-biotechnologies product pipeline, development of
scientifically validated bioactive nutraceuticals, derived from
Indian medicinal plants, as well as the development of a
pipeline of bio-similar drugs. Avesthagen has four strategic
business units: Biopharmaceuticals, Food for Medicine
(Bio-nutritionals), Seed for Food (agribiotech) and Science
Innovation. Avesthagen's partners include multiple top 10 global
companies in each of its fields of research.
Avesthagen collaborates at every stage in the value chain with
appropriate partners, both public and private, for access to and
exchange of technology and overall commercial expertise to
leverage the ‘India advantage’. |
|
